David Brookes
Executive Chair / Anatara Lifesciences
Most Notable Role
Dr David Brookes has experience in the health and biotechnology industries. He first became involved in the biotechnology sector in the late 1990s as an analyst, and continues to be a clinician and as a biotechnology industry consultant.
Dr Brookes has since held board positions in numerous ASX-listed biotechnology companies including as chair of genomics solutions company RHS, which was acquired by PerkinElmer Inc (NYSE:PKI $9B biotech company) in June 2018. He has also been a chair and member of several risk and audit committees in ASX-listed companies.
Dr Brookes is a Fellow of the Australian College of Rural and Remote Medicine, and a Fellow of the Australian Institute of Company Directors.
